Suggest Saving PCSK9 Inhibitors for Patients With Familial Hypercholesterolemia

You'll see Praluent ( PRAL-you-ent, alirocumab), the new PCSK9 inhibitor for high cholesterol in Canada.

It's the second PCSK9 inhibitor after Repatha (evolocumab).

These work by preventing PCSK9...proprotein convertase subtilisin kexin type 9...from binding and degrading LDL receptors in the liver. This allows the liver to clear more LDL cholesterol from the blood.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote